Combination Regimens: Reimbursement Challenges and Solutions

Combination therapy is the use of two or more therapies with the intention of improving patient health which are increasingly becoming more prevalent in the health system. Combination therapies can be produced by a single manufacturer but often the various components of the combination are produced by different companies which creates complexities in terms of pricing and reimbursement arrangements. This is a growing area of policy attention internationally with countries taking different paths to addressing the problem. The Institute of Health Economics conducted a workshop in 2022 to examine a path forward to create a made-in-Canada approach and outlined some foundational activities required to be prepared to address this issue. The work included some background research and an invitational forum with public and private sector partners supported by and developed in partnership with Pfizer Canada ULC, Amgen Canada Inc., GlaxoSmithKline Inc. (GSK Canada), AbbVie Corporation , J&J/Janssen.